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See related article on page 344. In less than its allotted 15 years, the US Human Genome Project hasproduced all of its promised products and then some, including a completedraft (minus a few pesky hard-to-clone regions) of the sequence of the 3.2billion nucleotides of DNA found in each haploid set of human chromo-somes. The publication of this draft sequence coincides with the 50thanniversary of the famous and famously brief letter to Nature by James
Watson and Francis Crick1 in which they proposed the double-helix model of DNA
structure. The human genome sequence, not to mention the sequences of the mouse
and a host of other eukaryotes and prokaryotes, represents an enormous amount of
information, only a fraction of which has been analyzed. Indeed, the work of
validating, cataloguing, comparing, and interpreting genetic information has
spawned a growth industry in the field now termed bioinformatics. Another deriv-
ative of the various genome projects around the world has been rapid advances in
bioinstrumentation. The most obvious example is the evolution of automated
machines that churn out nucleotide sequence data; the speed of sequencing in-
creased almost in proportion to the decrease in cost per nucleotide.
Other technologies evolved quickly as well. The first demonstration of hybrid-
izing samples of RNA or DNA in solution to short nucleotide sequences (oligonu-
cleotides) fixed to a glass slide occurred a decade ago.2 The platforms became
known as arrays or chips, and a variety of techniques was developed to construct
them. One popular technique combines photolithography with solid-phase chemis-
try. Tens or hundreds of thousands of different molecular probes can be affixed in
defined order to a support the size of a microscope slide cover slip. The probes can
be nucleic acids, proteins, or other molecules. Many are now commercially avail-
able, and one can order, for example, a chip to which are affixed oligonucleotides
representing all of the messenger RNAs known to be expressed in the normal human
liver. The processes of enabling hybridization with a test sample, detecting hybrid-
ization (usually by means of a fluorescent tag), recording the signals, and analyzing
the results have been automated. Thus the technique is within reach of any labora-
tory scientist with the funding to purchase either the equipment or the services of an
institutional core laboratory. A single experiment produces an enormous quantity of
data, and managing and interpreting the results have provided further job security
for those who practice bioinformatics. Array technology is being applied to a
multitude of purposes, including DNA sequencing, detection of mutations, drug
discovery, and comparison of one person’s, or one species’, genome with another.
During the mid-1990s, a handful of articles was published on array technology. For
January 2003 alone, a MEDLINE search found over 250 articles using oligonucle-
otide arrays.
The article by Absi and colleagues3 in this issue of the Journal illustrates one
application of oligonucleotide arrays, expression analysis. At the most fundamental
level, cells of different tissues differ from one another genetically in terms of which
genes are active, or expressing, at a given time. Gene expression produces RNA; in
some instances, RNA is the final product, but usually the RNA is a message that gets
translated into a protein. The amount of final product of gene expression present in
a tissue or an organ reflects both the rate of transcription of RNA from the gene and
the stability of this message. In the first instance gene expression is controlled by the
fundamental mechanisms of development and differentiation. However, tissues and
organs, especially when they are of interest to physicians, are rarely pristine in terms
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of which genes are active and, for those that are active, how
vigorously they are being transcribed. Pathologic processes,
whether intrinsic (eg, malignancy) or extrinsic (eg, infec-
tion), activate some genes and suppress transcription of
others. In turn, attempts by the body to remedy the pathol-
ogy (eg, immune responses and fibrosis) affect the expres-
sion of yet other genes. For any given disease in any given
tissue, an effort to analyze gene expression, either qualita-
tively or quantitatively, must account for all of these effects.
This creates a conundrum for those surgeons who are
interested in the causes and pathogeneses of the diseases
they treat and have access to impressive quantities (from a
molecular biologist’s perspective) of diseased tissue. If one
examines the genes that are turned on and off in a surgical
specimen, the result will often reflect the end stage of the
pathology, in which much of what is observed is a reaction
to, rather than the cause of, the disease. Controls are crucial
when comparisons are made among patients, with age, sex,
and stage of disease being obvious parameters. But diffi-
culties persist in studying a single patient: simply analyzing
a specimen of adjoining normal tissue will not solve the
problem of distinguishing epiphenomena from real patho-
genesis. Most progress with expression arrays is being made
in situations in which the histologic progression is certain
and samples can be obtained from all intervening stages. For
example, within a single surgical field, a patient with famil-
ial adenomatous polyposis might exhibit normal colonic
mucosa, mucosal dysplasia, adenoma, adenocarcinoma, and
metastasis.
Unfortunately, for those of us interested in aortic dis-
eases, neither this neat pathologic sequence nor the avail-
ability of contiguous informative specimens is feasible.
Moreover, the aorta, throughout its length, is not a homo-
geneous organ in terms of embryology, physical elastic
properties, and biochemical composition. The histopatho-
logic characteristics of the most common form of aneurysm
in the ascending aorta (ie, medial degeneration, previously
and incorrectly termed “cystic medial necrosis”) differ
markedly from those of the typical abdominal aortic aneu-
rysm (inflammatory and atherosclerotic). Recent studies of
gene expression in resected specimens of abdominal aortic
aneurysm have revealed considerable differences when
compared with nondilated specimens.4,5 Increased expres-
sion of a matrix metalloproteinase came as little surprise
because immunohistopathologic studies had indicated in-
creased levels of this protein in the aneurysm wall. How-
ever, what increased expression of, for example, CD86
antigen and decreased expression of neuronal pentraxin II
mean about the pathogenesis of abdominal aortic aneurysm
remain anyone’s guess. A recent study comparing expres-
sion in acute ascending aortic dissection with that in aortas
from organ donors leaves the same sense of frustration.6
The article by Absi and colleagues3 tackles a much larger
purview: comparing aneurysms in quite distinct regions of
the aorta. Given the marked epidemiologic and histopatho-
logic distinctions between aneurysms of the ascending and
abdominal aortas, the finding of markedly different expres-
sion profiles comes as no surprise. However, as the authors
caution to some extent, the differences might reflect more
than distinct causation. First, the ages of the subjects were
highly varied, with younger patients disproportionately rep-
resented in the ascending aortic specimens. To what extent
do the expression patterns in the abdominal aortic tissue
represent aging phenomena as opposed to pathology spe-
cific to aneurysm formation?
Second, patients with abdominal aortic aneurysms fre-
quently have intercurrent illnesses, both chronic and acute.
Can the expression profile be altered by these factors com-
pared with the profile in pure aneurysmal disease (if this
exists outside of rare hereditary disorders)? The best control
specimens need to be matched not only for specific ana-
tomic location (ie, infrarenal vs suprarenal), age, and sex but
also for blood pressure, smoking status, degree of athero-
sclerosis, medication use, and so forth.
Third, the numerous contributors to experimental vari-
ability need to be a constant concern. Most arrays contain
multiple spots for each probe, and the results from several
hybridizations are averaged. However, there has been little
attention to variability within a single specimen from the
same patient. The investigation of Absi and colleagues3
provides little information with regard to intraindividual
variation and demonstrates a fair amount of interindividual
variation among patients with the same histopathologic
appearance.
Finally and most importantly, the data are descriptive. To
be fair, hypothesis-driven experiments on aortic diseases
currently can only be done in animal models or in vitro by
using cultured human cells or pieces of tissue,7 all of which
could be of limited relevance to human disease.
We now possess a vast array of data (witness Tables 1
and 2 of the article by Absi and colleagues3) about differ-
ential gene expression in different forms of aortic aneurysm,
but what the data tell us about cause and pathogenesis
remains to be elucidated.
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